PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33508621-5	2021	The underlying mechanisms of nigericin also include the inactivation of Wnt/beta-catenin signals, blockade of Androgen Receptor (AR) signaling, and activation of Stress-Activated Protein Kinase/c-Jun N-terminal Kinase (SAPK/JNK) signaling pathways.	Nigericin	29-38	androgen receptor	Homo sapiens	110-127	
33508621-5	2021	The underlying mechanisms of nigericin also include the inactivation of Wnt/beta-catenin signals, blockade of Androgen Receptor (AR) signaling, and activation of Stress-Activated Protein Kinase/c-Jun N-terminal Kinase (SAPK/JNK) signaling pathways.	Nigericin	29-38	androgen receptor	Homo sapiens	129-131	
20709811-0	2010	Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.	Nigericin	82-91	androgen receptor	Homo sapiens	61-78	
20709811-6	2010	Our chemical library screening revealed that the antibiotic nigericin inhibits AR-mediated activation of the PSA promoter and PSA production in prostate cancer cells.	Nigericin	60-69	androgen receptor	Homo sapiens	79-81	
20709811-7	2010	Nigericin suppressed the androgen-dependent LNCaP cell growth even though the cells expressed a flutamide-resistant mutant AR.	Nigericin	0-9	androgen receptor	Homo sapiens	123-125	
20709811-10	2010	It is noteworthy that nigericin was able to mimic the knockdown of both AR isoforms: it reduced the expression of the full-length and the truncated ARs, and it induced G(1) cell-cycle arrest and apoptosis of 22Rv1 cells.	Nigericin	22-31	androgen receptor	Homo sapiens	72-74	
20709811-11	2010	These observations suggest that nigericin-like compounds that suppress AR expression at the mRNA level could be applied as new-type therapeutic agents that inhibit a broad spectrum of AR variants in HRPC.	Nigericin	32-41	androgen receptor	Homo sapiens	71-73	
20709811-11	2010	These observations suggest that nigericin-like compounds that suppress AR expression at the mRNA level could be applied as new-type therapeutic agents that inhibit a broad spectrum of AR variants in HRPC.	Nigericin	32-41	androgen receptor	Homo sapiens	184-186